US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy

  • Autotaxin inhibitor, IOA-289, recently received the proposed INN cambritaxestat
  • Cambritaxestat is in the Phase I AION-02 trial in combination with chemotherapy in metastatic pancreatic cancer
  • It is the first autotaxin inhibitor to be investigated in cancer patients

Amsterdam, The Netherlands and Geneva, Switzerland, 7 March 2024 – iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer therapies, today announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer.

Read more…